

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/001993

International filing date: 21 January 2005 (21.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US

Number: 60/538,993

Filing date: 23 January 2004 (23.01.2004)

Date of receipt at the International Bureau: 20 May 2005 (20.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1320384

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 12, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.


APPLICATION NUMBER: 60/538,993

FILING DATE: *January 23, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/01993*



Certified by



Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EU404285445US

| INVENTOR(S)   |                        |   |  |                               |              |
|---|------------------------|---|--|-------------------------------|--------------|
| Given Name (first and middle (if any))  | Family Name or Surname | Residence<br>(City and either State or Foreign Country)           |  |                               |              |
| Pamela<br>Liwei   | Dunn<br>Hi             | Toronto, Ontario, Canada<br>Toronto, Ontario, Canada              |  |                               |              |
| <input checked="" type="checkbox"/> Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto   |                        |   |  |                               |              |
| TITLE OF THE INVENTION (500 characters max)   |                        |   |  |                               |              |
| CYTOTOXICITY ASSAY  |                        |   |  |                               |              |
| Direct all correspondence to:   |                        | CORRESPONDENCE ADDRESS  |  |                               |              |
| <input type="checkbox"/> Customer Number  |                        | <input type="text"/> →  |  |                               |              |
| OR  |                        | <input type="text"/> Place Customer Number<br>Bar Code Label here |  |                               |              |
| <input checked="" type="checkbox"/> Firm or<br>Individual Name  |                        | Patrick J. Halloran   |  |                               |              |
| Address   |                        | Aventis Pasteur, Inc.   |  |                               |              |
| Address   |                        | Discovery Drive, Knerr Building                                   |  |                               |              |
| City  | Swiftwater             | State   | PA                                       | ZIP                           | 18370        |
| Country   | USA                    | Telephone   | 570-839-5446                             | Fax                           | 570-895-2702 |
| ENCLOSED APPLICATION PARTS (check all that apply)   |                        |   |  |                               |              |
| <input checked="" type="checkbox"/> Specification Number of Pages   |                        | 8   | <input type="checkbox"/> CD(s), Number   | <input type="text"/>          |              |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets   |                        | 16  | <input type="checkbox"/> Other (specify) | <input type="text"/>          |              |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76  |                        |   |  |                               |              |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT  |                        |   |  |                               |              |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.<br><input type="checkbox"/> A check or money order is enclosed to cover the filing fees<br><input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <input type="text"/> |                        |   |  | FILING FEE AMOUNT (\$)        |              |
| <input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.  |                        |   |  | <input type="text"/> \$160.00 |              |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.   |                        |   |  |                               |              |
| <input checked="" type="checkbox"/> No.<br><input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____   |                        |   |  |                               |              |

Respectfully submitted,

Date 

SIGNATURE

TYPED or PRINTED NAME REGISTRATION NO.  
(if appropriate)  
Docket Number:TELEPHONE **USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

31353  
60/538993  
012304  
U.S.P.T.O.  
176

012304

## PROVISIONAL APPLICATION COVER SHEET

### Additional Page

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|               |              |
|---------------|--------------|
| Docket Number | API-04-01-PR |
|---------------|--------------|

#### INVENTOR(S)/APPLICANT(S)

| Given Name (first and middle [if any]) | Family or Surname | Residence<br>(City and either State or Foreign Country) |
|--|-------------------|---|
| Laszlo                                 | Radvanyi          | Toronto, Ontario, Canada                                |
| Danielle                               | Salha             | Toronto, Ontario, Canada                                |

Number 2 of 2

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU404285445US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**(DOCKET NO. API-04-01-PR)**

5

**TITLE:** **CYTOTOXICITY ASSAY**

**INVENTORS:** **Pamela Dunn**  
**Toronto, Canada**

10

**Liwei He**  
**Toronto, Canada**

15

**Laszlo Radvanyi**  
**Toronto, Canada**

**Danielle Salha**  
**Toronto, Canada**

20

**ASSIGNEE:** **Aventis Pasteur, Ltd.**  
**Toronto, Ontario, Canada, M2R 3T4**

25

## CYTOTOXICITY ASSAY

### Field of the Invention

The present invention relates to methods for detecting CTL activity using flow 5 cytometry.

### Background of the Invention

The  $^{51}\text{Cr}$ -release assay has been the gold standard to measure CTL activity during an immune response for over 3 decades. However, the assay has a number of technical 10 limitations and recent data has brought into question the physiological relevance of the  $^{51}\text{Cr}$ -release assay and whether it is a true measure of CTL activity measured against target cells *in vivo*, especially in solid tumors. The lysis of target cells in *in vitro* CTL assays can be induced via two distinct mechanisms: 1) A membranolysis process mediated when perforin is simply inserted into the target cell membrane; and, 2) DNA 15 fragmentation (apoptosis) induced by the action of Granzyme B and Granzyme A entering a target cell via perforin and/or vesicle fusion events at the target cell surface. The  $^{51}\text{Cr}$ -release assay measures the first of these two read-outs. The latter mechanism has more physiologic relevance and is required *in vivo* for target cell killing. Recent 20 observations indicate that measurement of effector cell cytotoxicity by the  $^{51}\text{Cr}$ -release assay may not be accurate or in some cases, even relevant. Based on these observations, the investigator must remain cognizant of the fact that effector cells determined to be cytotoxic based on  $^{51}\text{Cr}$ -release assays may indeed not be CTL capable of tumor cell killing via DNA fragmentation *in vivo*. This may account for many of the results in the cancer immunotherapy literature in which effector cell responses monitored *in vitro* may 25 not correlate with vaccine efficacy in the patient. For example, peptide vaccines selected by virtue of positive effector cell cytotoxicity date generated using  $^{51}\text{Cr}$ -release assays may not accurately reflect the actual epitopes active in inducing CTL lysis *in vivo* via DNA fragmentation. In addition, there are a number of other issues plaguing the use of 30  $^{51}\text{Cr}$ -based assays, including the need to use hazardous radioactivity, and problems related to the use of scintillation counters.

January 23, 2004

U.S. Express Mail No. EU40428544SUS

The JAM assay is a newer method that solves some of the issues with <sup>51</sup>Cr-release. Although it measures DNA fragmentation effectively, it has serious limitations due to the need to label the DNA of target cells with agents such as <sup>3</sup>H-thymidine or <sup>125</sup>I-deoxyuridine. This method invariably causes DNA damage and changes the physiology of the target cell before the CTL assay. In addition, the <sup>3</sup>H-thymidine labelling method does not afford the same degree of sensitivity as <sup>51</sup>Cr and <sup>125</sup>I is a dangerous agent requiring considerable lead shielding of both the lab worker as well as the lab area. Overall, a non-radioactive method to measure apoptosis induction and DNA fragmentation in target cells during CTL attack would be a more ideal assay, especially when contemplating its use in clinical trial monitoring.

Detection of caspase cleavage using fluorogenic caspase substrates has also been used to demonstrate cytotoxic T cell activity (Liu, et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nautre Medicine, Jan. 2003, 9(1):4-5.) In addition, other highly sensitive methods to enumerate antigen-specific CD8<sup>+</sup> T-cells have been introduced, such as intracellular cytokine staining, the ELISPOT assay, and staining for T-cells using class I MHC tetramers. However, these assays do not measure ultimate cytolytic function, which is especially important in analyzing anti-tumor immune responses. Assays offering a suitable levels of sensitivity, specificity, safety and ease-of-use are lacking. A new and sensitive assay system for detecting CTL activity is provided herein.

#### Summary of the Invention

The present invention provides a cytotoxicity assay that detects DNA fragmentation- and/or apoptosis-related changes in target cells following contact with effector cells. In one embodiment, the assay is conducted using one or more reagents that detect cleavage of a caspase or phosphorylation of histones. In a preferred embodiment, cleavage of caspase is detected using a monoclonal antibody. In another preferred embodiment, phosphorylation of histones is detected using a monoclonal antibody. In other embodiments, cleaved caspase and/or phosphorylated histones are detected using at least one monoclonal antibody coupled with flow cytometric analysis.

**Brief Description of the Drawings**

Figure 1. Assay protocol.

Figure 2. Flow cytometric analysis of data.

Figure 3. Assay conducted using P815 target cells.

5 Figure 4. Mouse MLR CTL activity.

Figure 5. Antigen-Specific Mouse CTL Assay.

Figure 6. Assessment of the immune response to TRP2 peptide linked to hPER1 PTD sequence.

Figure 7. Peptide-Specific Mouse CTL Assay.

10 Figure 8. Human T Cell Activation Assay.

Figure 9. Human CTL Assay Results.

Figure 10. Dilution of Effectors with Naïve Cells.

Figure 11. Dilution of Effectors with Naïve Splenocytes.

Figure 12. CTL Activity in Mouse MLR: Diluted Effects.

15 Figure 13. Sensitivity of Caspase-3 Assay in Effector Dilution.

Figure 14. Flow cytometric analysis of a two-hour target/effectector incubation.

Figure 15. Flow cytometric analysis of a four-hour target/effectector incubation.

Figure 15. Flow cytometric analysis of a six-hour target/effectector incubation.

20 **Detailed Description**

The present invention relates to reagents and assays for performing cytotoxicity assays. The assays are suitable to detecting cytotoxicity mediated by immune effector cells including but not limited to T cells, natural killer (NK) cells, granulocytes, monocytes, macrophages, and the like. The assays are generally based on the detection 25 of DNA fragmentation- and/or apoptosis-related changes in a target cell. For instance, in certain embodiments, cleavage of an enzyme involved in the apoptotic process is detected. In another, a change in the characteristic of a DNA-associated protein during the apoptotic process is detected. Such changes are suitable to detection using devices that measure cell fluorescence, such as a Fluorescence Activated Cell Sorter (FACS) 30 machine or flow cytometer.

January 23, 2004

U.S. Express Mail No. EU404285445US

In one embodiment, the present invention relates to an assay for measuring the cleavage of one or more caspases during the apoptotic process. Caspases shown to play a role in apoptosis that may be suitable for detection in an assay as shown herein may include but are not limited to caspase 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14. In 5 one embodiment, caspase 3 is detected using the assay described herein. Another enzyme known to be cleaved during the apoptotic process is poly-ADP ribose polymerase (PARP). Cleavage of caspases, in particular caspase 3, and PARP are early events during apoptosis and are triggered in CTL targets. In addition to the cleavage of caspases and PARP, a number of intracellular substrates are phosphorylated during the induction of 10 apoptosis. For instance, histone H2A.X is phosphorylated in wide variety of cell lineages. Antibodies with specific binding capacity for cleaved caspases, as well as antibodies specific for phosphorylated histone H2.AX are commercially available and suitable for use in practicing the present invention.

In certain embodiments, dyes are utilized to stain the target cells prior to contact 15 with effector cells. Suitable dyes include Vial T, CFSE, and DDAO-SE, each of which are known in the art. A preferred dye is DDAO-SE (Molecular Probes). Other suitable dyes are also known in the art and may be useful in practicing the present invention.

In one embodiment, the assay of the present invention provides is carried out by: 20 1) preparing effector cells (E); 2) preparing target cells (T), including tagging the cells with a detectable marker such as a fluorescent dye; 3) mixing the effector cells and the target cells at a sufficient number of E:T ratios; 4) incubating the mixture for a sufficient period of time and under conditions suitable for at least some of the effector cells to become cytotoxic toward at least some of the target cells; 5) fixing and permeabilizing the mixed cells; 6) staining the cells with a detectable reagent having the ability to bind a 25 protein or fragment thereof that undergoes a change during or results from the apoptotic process; and, 7) detecting the detectable reagent. In certain embodiments, the detectable reagent is detectable by virtue of a fluorescent tag or moiety contained within the reagent or by detecting a secondary reagent that binds to the detectable reagent, the secondary reagent being detectable by virtue of a fluorescent tag or moiety contained within the 30 secondary reagent. In preferred embodiments, the detectable reagent and / or the secondary reagent is an antibody, which may be fluorescently labeled. The detectable

reagent may be detected by any of several well-known methods including but not limited to FACS. In one preferred embodiment, the detectable reagent is an anti-Caspase 3 antibody (such as the PE Conjugated Monoclonal Rabbit Anti-Active Caspase 3 Antibody, BD Pharmingen Catalog No. 550914). Other suitable reagents are known in the art.

In certain embodiments, it may be beneficial or desirable to contact or "pulse" a target cell with a peptide to which the effector cells may respond prior to staining the target cells and / or mixing the target and effector cells. For instance, a target cell may be pulsed with a peptide corresponding to the amino acid sequence of an infectious agent, such as HIV or a tumor antigen. Suitable tumor antigens include, for example, gp100 (Cox et al., *Science*, 264:716-719 (1994)), MART-1/Melan A (Kawakami et al., *J. Exp. Med.*, 180:347-352 (1994)), gp75 (TRP-1) (Wang et al., *J. Exp. Med.*, 186:1131-1140 (1996)), tyrosinase (Wolfel et al., *Eur. J. Immunol.*, 24:759-764 (1994)), NY-ESO-1 (WO 98/14464; WO 99/18206), melanoma proteoglycan (Hellstrom et al., *J. Immunol.*, 130:1467-1472 (1983)), MAGE family antigens (i.e., MAGE-1, 2,3,4,6, and 12; Van der Bruggen et al., *Science*, 254:1643-1647 (1991); U.S. Pat. Nos. 6,235,525), BAGE family antigens (Boel et al., *Immunity*, 2:167-175 (1995)), GAGE family antigens (i.e., GAGE-1,2; Van den Eynde et al., *J. Exp. Med.*, 182:689-698 (1995); U.S. Pat. No. 6,013,765), RAGE family antigens (i.e., RAGE-1; Gaugler et al., *Immunogenetics*, 44:323-330 (1996); U.S. Pat. No. 5,939,526), N-acetylglucosaminyltransferase-V (Guilloux et al., *J. Exp. Med.*, 183:1173-1183 (1996)), p15 (Robbins et al., *J. Immunol.*, 154:5944-5950 (1995)),  $\beta$ -catenin (Robbins et al., *J. Exp. Med.*, 183:1185-1192 (1996)), MUM-1 (Coulie et al., *Proc. Natl. Acad. Sci. USA*, 92:7976-7980 (1995)), cyclin dependent kinase-4 (CDK4) (Wolfel et al., *Science*, 269:1281-1284 (1995)), p21-ras (Fossum et al., *Int. J. Cancer*, 56:40-45 (1994)), BCR-abl (Bocchia et al., *Blood*, 85:2680-2684 (1995)), p53 (Theobald et al., *Proc. Natl. Acad. Sci. USA*, 92:11993-11997 (1995)), p185 HER2/neu (erb-B1; Fisk et al., *J. Exp. Med.*, 181:2109-2117 (1995)), epidermal growth factor receptor (EGFR) (Harris et al., *Breast Cancer Res. Treat.*, 29:1-2 (1994)), carcinoembryonic antigens (CEA) (Kwong et al., *J. Natl. Cancer Inst.*, 85:982-990 (1995) U.S. Pat. Nos. 5,756,103; 5,274,087; 5,571,710; 6,071,716; 5,698,530; 6,045,802; EP 263933; EP 346710; and, EP 784483); carcinoma-associated mutated mucins (i.e.,

MUC-1 gene products; Jerome et al., *J. Immunol.*, 151:1654-1662 (1993)); EBNA gene products of EBV (i.e., EBNA-1; Rickinson et al., *Cancer Surveys*, 13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing et al., *J. Immunol.*, 154:5934-5943 (1995)); prostate specific antigen (PSA; Xue et al., *The Prostate*, 30:73-78 (1997)); prostate specific membrane antigen (PSMA; Israeli, et al., *Cancer Res.*, 54:1807-1811 (1994)); 5 idiotypic epitopes or antigens, for example, immunoglobulin idiotypes or T cell receptor idiotypes (Chen et al., *J. Immunol.*, 153:4775-4787 (1994)); KSA (U.S. Patent No. 5,348,887), kinesin 2 (Dietz, et al. *Biochem Biophys Res Commun* 2000 Sep 7;275(3):731-8), HIP-55, TGF $\beta$ -1 anti-apoptotic factor (Toomey, et al. *Br J Biomed Sci* 2001;58(3):177-83), tumor protein D52 (Bryne J.A., et al., *Genomics*, 35:523-532 (1996)), H1FT, NY-BR-1 (WO 01/47959), NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-10 87 and NY-BR-96 (Scanlan, M. *Serologic and Bioinformatic Approaches to the Identification of Human Tumor Antigens*, in *Cancer Vaccines 2000*, Cancer Research Institute, New York, NY), among others, including wild-type, modified, mutated versions 15 thereof.

In certain embodiments, the time during which the target and effector cells are incubated may be modified. For instance, it may be desirable to incubate the mixture for one, two, three, four, five, six or more hours prior to further analysis.

Other aspects of the present invention include kits for carrying out the assays 20 described herein. A kit may include materials useful in preparing effector cells, a suitable number of effector cells, a fluorescent dye with which to stain the target cells, a device such as a 96-well plate in which the target and effector cells may be mixed and incubated, materials required for fixing and permeabilizing the cells, a detectable reagent, and / or a secondary reagent. Different combinations of such materials may be organized as a kit in 25 order to aid the skilled artisan in carrying out the assay of the present invention.

A better understanding of the present invention and of its many advantages will be had from the following examples, given by way of illustration.


#### EXAMPLES

30 A sensitive flow cytometry-based assay for the measurement of antigen-specific CTL function based on the activation of caspase 3 and/or the phosphorylation of histones

(histone H2A.X) in target cells induced to undergo apoptosis by CTL through the action of perforin and granzymes is described below. As outlined in Figs. 1, 5, and 8, target cells were labeled with the cell membrane tracking dye called DDAO-SE (Molecular Probes), incubated with CTL, fixed, permeabilized, and stained with with an antibody 5 recognizing cleaved caspase 3 and/or phosphorylated histone H2A.X. The cells were then assayed by flow cytometry. The assay was tested in a number of different human and mouse systems generating antigen-specific CD8<sup>+</sup> T-cells, including allogeneic responses and peptide-specific T-cell responses induced *in vitro*, or after vaccination in mice (Figs. 2-4, 6, 7, and 9). The assay was found to be as sensitive as MHC tetramer-based methods with detection of antigen-specific CTL activity at frequencies on the order 10 of 0.25 to 0.1% (1:400 to 1:1,200) (Figs. 10-16). When murine peptide-specific CTL responses were determined *ex vivo* in cell suspensions from peptide-immunized mice, the new assay exhibited sensitivities equal to or greater than <sup>51</sup>Cr-release with lower backgrounds. These results suggest that this flow cytometry-based assay is a powerful 15 tool to determine CTL responses in clinical trial monitoring as well as pre-clinical experiments of CTL function. The assay also has the advantage of also tracking the fate of the CTL effector cells and can be improved by staining for additional products of apoptosis in target cells.

20 While the present invention has been described in terms of the preferred embodiments, it is understood that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that come within the scope of the invention as claimed.


## FIGURE 1 Assay Protocol



## FIGURE 2

### Flow Cytometry Data Analysing Methods


API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU40428545US



### FIGURE 3

### Targets: P815


API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU0428545US



## FIGURE 4

### Mouse MLR CTL Activity


API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU404285445US



Incubation Time of Targets & Effectors

**FIGURE 5**  
**Antigen Specific Mouse CTL Assay**

API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU40428544SUS




**FIGURE 6**  
**STUDY DS-27**  
**Assessment of immune response to TRP2 peptide-linked to hPER1-PTD sequence**

| Group | #of mice | Procedure  |
|-------|----------|--|
| A     | 4        | Day 0: s.c. injection of 50nmoles TRP2 + 50nmoles of CLP243 in 4 mice<br>Day 21: Boost<br>Day 42: harvest 4 spleens              |
| B     | 4        | Day 0: s.c. injection of 50nmoles hPER1- FVYVW-TRP2 + 50nmoles of CLP243 in 4 mice<br>Day 21: Boost<br>Day 42: harvest 4 spleens |
| C     | 4        | Day 0: s.c. injection of 50nmoles hPER1-L-TRP2 + 50nmoles of CLP243 in 4 mice<br>Day 21: Boost<br>Day 42: Harvest 4 spleens      |
| D     | 4        | Day 0: s.c. injection of 50nmoles hPER1-TRP2 + 50nmoles of CLP243 in 4 mice<br>Day 21: Boost<br>Day 42: Harvest 4 spleens        |
| E     | 4        | Day 0: s.c. injection of 50nmoles TRP2 + 50nmoles of CLP243 in IFA in 4 mice<br>Day 21: Boost<br>Day 42: Harvest 4 spleens       |

U.S. Express Mail No. EU404285445US  
January 23, 2004  
API-04-01-PR


FIGURE 7

## Peptide-specific Mouse CTL Assay




## FIGURE 8

### Human T cell Activation CTL Assay




U.S. Express Mail No. EU404285445US  
January 23, 2004  
API-04-01-PR

**FIGURE 9**  
**Human CTL Assay Results**



## FIGURE 10

### Dilution of Effectors with Naïve Cells




## FIGURE 11

### Dilution of Effectors with Naïve Splenocytes

| Effector B6: Naïve B6 | # Effector B6 /well | # Naïve B6/well | P815: Effector B6 |
|-----------------------|---------------------|-----------------|-------------------|
| Effector B6 only      | 150,000             | 0               | 1:1               |
| 1:1                   | 75,000              | 75,000          | 2:1               |
| 1:3                   | 37,500              | 112,500         | 4:1               |
| 1:7                   | 18,750              | 131250          | 8:1               |
| 1:15                  | 9,375               | 140,625         | 16:1              |
| 1:31                  | 4,688               | 145,312         | 32:1              |
| 1:63                  | 2,344               | 147,656         | 64:1              |
| 1:99                  | 1,500               | 148500          | 100:1             |
| 1:199                 | 750                 | 149250          | 200:1             |
| Naïve B6 only         | 0                   | 150,000         | 1:0               |

## FIGURE 12



### FIGURE 13


#### Sensitivity of Caspase-3 Assay in Effector Dilution

| B6 effector:<br>B6 naive | Effector B6 in<br>Total Cells (%) | Frequency of Caspase-3 Positive Targets detected in total<br>cells (%) |       |       |
|--------------------------|-----------------------------------|--|-------|-------|
|                          |                                   | 2hr  | 4hr   | 6hr   |
| Effector B6<br>alone     | 50                                | 26.90  | 33.33 | 41.88 |
| 1:1                      | 25                                | 17.58  | 21.57 | 33.58 |
| 1:3                      | 12.5                              | 10.26  | 13.81 | 20.49 |
| 1:7                      | 6.25                              | 5.99   | 7.61  | 11.05 |
| 1:15                     | 3.13                              | 3.03   | 4.41  | 5.75  |
| 1:31                     | 1.56                              | 1.56   | 2.27  | 3.48  |
| 1:63                     | 0.78                              | 0.98   | 1.35  | 2.09  |
| 1:99                     | 0.5                               | 0.68   | 1.03  | 1.60  |
| 1:199                    | 0.25                              | 0.58   | 0.79  | 1.56  |
| Naive B6<br>alone        | 0                                 | 0.16   | 0.19  | 0.45  |

# FIGURE 14

## 2hr Incubation


API-04-01-PR  
 January 23, 2004  
 U.S. Express Mail No. EU404285445US



# FIGURE 15

## 4hr Incubation

API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU40428345US



# FIGURE 16

## 6hr Incubation

API-04-01-PR  
January 23, 2004  
U.S. Express Mail No. EU404283445US

